RxDoctor Payments Data

Nita Paintal, MD

Psychiatry · la Mesa, CANPI 1497795223

Payments from drug & device makers

$3,216in general payments, 2019–2025

Across 174 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$360
  • Takeda Pharmaceuticals U.S.A., Inc.$341
  • AbbVie$264
  • Lundbeck LLC$256
  • Teva Pharmaceuticals USA, Inc.$249
  • Johnson & Johnson$206
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,18999%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,216 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$46,995
Medicare patients
169
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$284,577
TrintellixVortioxetine Hydrobromide53$39,282
Invega SustennaPaliperidone Palmitate12$38,083
FanaptIloperidone14$25,272
BelsomraSuvorexant44$24,158
Aripiprazole182$20,402
Bupropion XlBupropion Hcl525$15,504
Duloxetine Hcl382$15,277
Quetiapine Fumarate711$14,082
Desvenlafaxine Succinate ErDesvenlafaxine Succinate105$11,860
Vilazodone Hcl78$11,595
QuviviqDaridorexant Hcl16$8,557
Lamotrigine378$6,786
Venlafaxine Hcl ErVenlafaxine Hcl261$5,335
Trazodone Hcl561$5,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$114$284,57734 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$341$39,28253 claims
Johnson & JohnsonInvega Sustenna$206$38,08312 claims
Vanda Pharmaceuticals Inc.Fanapt$151$25,27214 claims
MerckBelsomra$183$24,15844 claims
Idorsia Pharmaceuticals US IncQuviviq$91$8,55716 claims
Almatica Pharma LLCSertraline Hcl$65$5,193525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →